Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T, Gibbs P, Sieber O, Waring P, Desai J. Day F, et al. Among authors: williams d. Target Oncol. 2015 Mar;10(1):99-109. doi: 10.1007/s11523-014-0319-8. Epub 2014 May 27. Target Oncol. 2015. PMID: 24859797 Free PMC article.
DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Tögel L, Nightingale R, Wu R, Chüeh AC, Al-Obaidi S, Luk I, Dávalos-Salas M, Chionh F, Murone C, Buchanan DD, Chatterton Z, Sieber OM, Arango D, Tebbutt NC, Williams D, Dhillon AS, Mariadason JM. Tögel L, et al. Among authors: williams d. Sci Rep. 2018 Jan 29;8(1):1767. doi: 10.1038/s41598-018-20176-9. Sci Rep. 2018. PMID: 29379130 Free PMC article.
Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
Williams DS, Mouradov D, Jorissen RN, Newman MR, Amini E, Nickless DK, Teague JA, Fang CG, Palmieri M, Parsons MJ, Sakthianandeswaren A, Li S, Ward RL, Hawkins NJ, Faragher I, Jones IT, Gibbs P, Sieber OM. Williams DS, et al. Gut. 2019 Mar;68(3):465-474. doi: 10.1136/gutjnl-2017-315664. Epub 2018 Jan 30. Gut. 2019. PMID: 29382774
Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.
Williams DS, Mouradov D, Browne C, Palmieri M, Elliott MJ, Nightingale R, Fang CG, Li R, Mariadason JM, Faragher I, Jones IT, Churilov L, Tebbutt NC, Gibbs P, Sieber OM. Williams DS, et al. Mod Pathol. 2020 Mar;33(3):483-495. doi: 10.1038/s41379-019-0353-2. Epub 2019 Aug 30. Mod Pathol. 2020. PMID: 31471586 Free article.
Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation.
Williams DS, Mouradov D, Newman MR, Amini E, Nickless DK, Fang CG, Palmieri M, Sakthianandeswaren A, Li S, Ward RL, Hawkins NJ, Skinner I, Jones I, Gibbs P, Sieber OM. Williams DS, et al. Mod Pathol. 2020 Jul;33(7):1420-1432. doi: 10.1038/s41379-020-0496-1. Epub 2020 Feb 11. Mod Pathol. 2020. PMID: 32047231 Free article.
Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Tögel L, Nightingale R, Wu R, Chüeh AC, Al-Obaidi S, Luk I, Dávalos-Salas M, Chionh F, Murone C, Buchanan DD, Chatterton Z, Sieber OM, Arango D, Tebbutt NC, Williams D, Dhillon AS, Mariadason JM. Tögel L, et al. Among authors: williams d. Sci Rep. 2023 Feb 10;13(1):2422. doi: 10.1038/s41598-023-29328-y. Sci Rep. 2023. PMID: 36765160 Free PMC article. No abstract available.
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer.
Jenkins LJ, Luk IY, Chionh F, Tan T, Needham K, Ayton J, Reehorst CM, Vukelic N, Sieber OM, Mouradov D, Gibbs P, Williams DS, Tebbutt NC, Desai J, Hollande F, Dhillon AS, Lee EF, Merino D, Fairlie WD, Mariadason JM. Jenkins LJ, et al. Among authors: williams ds. Cell Death Dis. 2024 Mar 1;15(3):183. doi: 10.1038/s41419-024-06478-z. Cell Death Dis. 2024. PMID: 38429301 Free PMC article.
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK, Wirapati P, Asher R, Lee CK, Savas P, Price TJ, Townsend A, Hardingham J, Buchanan D, Williams D, Tejpar S, Mariadason JM, Tebbutt NC. Mooi JK, et al. Among authors: williams d. Ann Oncol. 2018 Nov 1;29(11):2240-2246. doi: 10.1093/annonc/mdy410. Ann Oncol. 2018. PMID: 30247524 Free article. Clinical Trial.
14,450 results
You have reached the last available page of results. Please see the User Guide for more information.